#USA #Washington #Clinical Trials #Healthy Americas #FDA Drug Trials

The Discrepancy in Drug Trials: A Call for Inclusivity

In a recent analysis by the Healthy Americas Foundation, it was revealed that crucial drug trials frequently fail to adequately include the diverse populations that will ultimately use these medications. This comprehensive report assessed 46 new drugs approved by the FDA in 2025, encompassing nearly 26,000 participants. The findings indicate striking disparities in patient representation, which may jeopardize the efficacy and safety of these life-altering treatments.

Key Findings from the Report

The report draws attention to several critical issues:

• - International Representation: Most participants in these trials were recruited outside of the United States. In pivotal studies focused on cancer, heart disease, blood, kidney issues, and endocrine disorders, only about 20% of participants were enrolled in the U.S.
• - Underrepresentation of Minorities: African American and Hispanic patients were often significantly underrepresented. For example, in over 38% of trials that reported ethnic backgrounds, Hispanic individuals constituted 5% or less of the participants.
• - Older Adults Neglected: Among those aged 65 or older, they only made up a quarter to a third of participants in cancer and cardiovascular studies, despite these conditions being more prevalent among the elderly.

A striking example mentioned involved a new drug for multiple myeloma—a cancer that disproportionately affects African Americans—being tested on just 11 such patients.

Despite these shortcomings, the report also highlights that inclusivity in trials is possible. Several 2025 studies successfully enrolled patients reflective of the disease’s demographics, with one pediatric trial even achieving 36% Hispanic enrollment for a rare condition.

Practical Solutions Proposed

The report advocates for bipartisanship in addressing these concerns, offering several actionable recommendations:

• - Set Enrollment Goals: Establish goals based on disease prevalence in specific populations, ensuring adequate representation from key demographic groups.
• - Provide Financial Support: Eliminate travel costs and out-of-pocket expenses that prevent patients from participating in clinical trials.
• - Report Ethnic Demographics: Mandate that trial results report participant demographics clearly, including both U.S.-based and international enrollment statistics.

Dr. Jane L. Delgado, President and CEO of the Healthy Americas Foundation, expressed urgency for these changes, stating, “A pivotal trial's singular purpose is to prove whether a medication is effective and safe for the individuals who will use it. Too often, evidence gathered comes from patients who do not align with the intended population.” She emphasized that when a treatment fails or causes harm, it is ultimately the patients and their families who suffer the consequences.

Conclusion

The new report underscores the need for a systematic overhaul in the way clinical trials are conducted to ensure they accurately reflect the populations that will be impacted by the approved medications. By implementing these solutions and fostering bipartisan support, the healthcare industry can improve patient safety and efficacy of treatments, making significant strides toward health equity across diverse populations.

For further insights into the report and its recommendations, visit Healthy Americas Foundation's website.